• Search
  • Helpdesk
  • Sales contact

Rare Disease case study

Last updated: May 7, 2025

Over 90% of rare diseases have no treatment… 

  • There are more than 6,000 known rare diseases…
  • Approximately 80% of them have a genetic component… 75% affect children…
  • And most rare diseases are chronic conditions, many of which progress overtime and are potentially fatal…

Understanding the rare disease framework is key to be able to offer study participants adapted solutions and as such, positively contribute to important and necessary clinical research conducted on rare diseases.

Kayentis offers an extensive experience in rare disease clinical trials, in indications such as:

  • Prader-Willi Syndrome
  • PIK3CA-related overgrowth spectrum
  • Auto-Immune Hepatitis (AIH)
  • Hypoparathyroidism
  • Sjögren’s syndrome
  • Acute Vertigo

Download the case study 👇
Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

ACDM 2026

MAR 15-17 2026 • Berlin, Germany
Booth #22 ACDM26 15-17 March 2026

C-PATH 2026

APR 16-17 2026 • Washington, D.C. USA

2026 Precision in Clinical Trials

APR 30 - MAY 1 2026 • Boston, MA, USA
Booth #3 Precision In Clinical Trials Summit | April 30 - May 1 - Boston

OCT Europe 2026

MAY 6-7 2026 • Barcelona, Spain
Booth #59 16th Annual Outsourcing in Clinical Trials Europe 2026 - Arena International

OCT East Coast 2026

MAY 12-13 2026 • New Brunswick, NJ, USA
Booth #7 17th Annual Outsourcing in Clinical Trials East Coast 2026 - Arena International

Patients as Partners 2026

MAY 19-20 2026 • London, UK
Patients as Partners EU

PCMG 2026

JUNE 16-17 2026 • Berlin, Germany
Register For PCMG26 Updates - PCMG 2026 Annual Assembly